Last Articles

Clovis Oncology.

Clovis Oncology, Avila Therapeutics announce advancement agreement for NSCLC EMSI program Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, commercializing and developing innovative anti-cancer agents, and Avila Therapeutics, Inc ., a biotechnology business designing targeted covalent drugs, announced today an agreement for the advancement and commercialization of Avila’s epidermal growth element receptor mutant-selective inhibitor program, presently in pre-clinical development for the treating non-small cell lung cancer .

.. Closer to effective screening for TB An Australian scientist provides effective screening for tuberculosis a step closer with his latest research in Vietnam – where he now lives and works. We still don’t know why only 1 in ten of both billion people transporting the Mycobacteria tuberculosis bacterium become ill with tuberculosis . But the disease kills several million people every year – three every minute worldwide. Centenary Institute researcher Dr Greg Fox is helping to find out by using a $150,000 grant from an anonymous benefactor to carry out a genetic study of TB sufferers and their own families in Vietnam, a country where 290,000 folks have TB and 54,000 die from it every single year. The function of genes in the chance of contracting TB is regarded as about 30-40 per cent – Greg wants to learn more.